Emergex, a biotechnology business located in the UK with its headquarters in Abingdon, is a leader in the development of set-point vaccinations to combat some of the most dangerous intracellular bacterial illnesses, Zika, Ebola, and Dengue Fever.

These population-based set-point vaccinations alter recipients’ initial immune status in a way that “primes” their immune systems to recognise subsequent infectious agents similarly to how a natural infection would, preventing an acute or severe manifestation of the disease.

In order to create its vaccines, Emergex combines proven technology with the most recent scientific findings. This includes using synthetic peptide codes that are determined on real infected cells and a unique gold nanoparticle carrier system for programming.